BIOFILCHEM vs KREBSBIO: Stock Comparison

BIOFIL CHEM & PHARMA vs KREBS BIOCHEMICALS & INDUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

KREBS BIOCHEMICALS & IND is the larger company by market capitalisation. BIOFIL CHEM & PHARMA shows a higher ROCE and a higher net margin, while KREBS BIOCHEMICALS & IND shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BIOFILCHEM leads 6; KREBSBIO leads 2 of 9

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BIOFILCHEMKREBSBIO

Valuation lens

What price are you paying?

Market CapContext only
₹52 Cr
₹121 Cr
P/E RatioSame reading
0x
P/B RatioSame reading
0x
EPSBIOFILCHEM has the higher reading
₹0.07
₹-1.15
Book ValueContext only
₹13.25
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
KREBSBIO is the larger company
₹121 Cr vs ₹52 Cr
EPS
BIOFILCHEM has higher earnings per share
₹0.07 vs ₹-1.15
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs -9.3%
EPS Growth (TTM YoY)
BIOFILCHEM has faster EPS growth
10.8% vs 0%
Qtr Sales Growth
BIOFILCHEM has stronger quarterly sales growth
-56.51% vs -70.57%
Qtr Profit Growth
KREBSBIO has stronger quarterly profit growth
85.33% vs -96.08%
ROCE
BIOFILCHEM has a higher ROCE
6.39% vs -15.89%
Net Margin
BIOFILCHEM has a higher net margin
9.81% vs -71.35%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOFILCHEMKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOFILCHEMKREBSBIO
Live Price₹32₹55.95
Day Change0.09%2.66%
Volume5,5435,830
52-Week High₹46.34₹82.49
52-Week Low₹25.6₹38.33
Distance from 52W High-30.95%-32.17%

Valuation

MetricBIOFILCHEMKREBSBIO
Market Cap₹52 Cr₹121 Cr
P/E Ratio0x
P/B Ratio0x
EPS₹0.07₹-1.15
Book Value₹13.25
Dividend Yield0%0%

Growth

MetricBIOFILCHEMKREBSBIO
Revenue Growth (TTM YoY)-9.3%11.6%
EPS Growth (TTM YoY)10.8%0%
Qtr Sales Growth-56.51%-70.57%
Qtr Profit Growth-96.08%85.33%

Profitability & Leverage

MetricBIOFILCHEMKREBSBIO
ROE12.92%
ROCE6.39%-15.89%
Net Margin9.81%-71.35%
Operating Margin12.18%-41.49%
Debt to Equity0.14x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOFILCHEMKREBSBIO
Promoter Holding46.79%72.74%
FII Holding0%0.5%
DII Holding0.08%0%
Public Holding53.13%26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BIOFIL CHEM & PHARMA and KREBS BIOCHEMICALS & IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.